{
  "ticker": "IOVA",
  "company_name": "Iovance Biotherapeutics",
  "sector": "Biotechnology",
  "market_cap_current": 0.85,
  "price_current": 2.20,
  "risk_score": {
    "overall": 8.0,
    "financial_risk": 8.5,
    "execution_risk": 8.0,
    "dilution_risk": 8.0,
    "competitive_risk": 7.0,
    "regulatory_risk": 6.5
  },
  "time_horizon_years": 3,
  "scenarios": {
    "bull": {
      "probability": 0.275,
      "description": "Successful scale-up, strong demand for Amtagvi, manufacturing optimization, margins >55%, revenues ~800M.",
      "price_target_low": 10,
      "price_target_high": 18,
      "price_target_mid": 14,
      "expected_market_cap": 5.0,
      "key_drivers": [
        "TIL therapy adoption accelerates",
        "Manufacturing scaling efficiencies",
        "Earlier-line approvals",
        "Expanding indications"
      ]
    },
    "base": {
      "probability": 0.40,
      "description": "Moderate commercialization success, 400â€“500M revenues, dilution continues but manageable.",
      "price_target_low": 3,
      "price_target_high": 4.5,
      "price_target_mid": 3.7,
      "expected_market_cap": 1.6,
      "key_drivers": [
        "Slow but steady growth",
        "Controlled dilution",
        "Stabilizing margins",
        "No major competitive shocks"
      ]
    },
    "bear": {
      "probability": 0.325,
      "description": "Weak uptake, heavy dilution, revenue stalls, financing risk, possible distress.",
      "price_target_low": 0.0,
      "price_target_high": 0.8,
      "price_target_mid": 0.4,
      "expected_market_cap": 0.3,
      "key_drivers": [
        "Demand fails to scale",
        "Financing becomes toxic",
        "Operational bottlenecks",
        "Regulatory or safety concerns"
      ]
    }
  },
  "expected_value": {
    "price_target_weighted": 5.5,
    "upside_vs_current_percent": 150.0
  },
  "fundamentals": {
    "cash_on_hand": 0.307,
    "runway_years": 1.8,
    "revenue_ttm": 0.25,
    "gross_margin": 0.43,
    "debt": null,
    "shares_outstanding": 362,
    "dilution_forecast_3yr": 450
  },
  "qualitative": {
    "strengths": [
      "First-in-class TIL therapy",
      "Strong clinical efficacy data",
      "Growing revenue",
      "Large total addressable market"
    ],
    "weaknesses": [
      "High cash burn",
      "Manufacturing complexity",
      "Single-product dependence"
    ],
    "opportunities": [
      "Expansion to new tumor types",
      "Earlier-line therapy",
      "Ex-US approvals",
      "Manufacturing automation"
    ],
    "threats": [
      "Competition from next-gen cell therapies",
      "Financing risk",
      "Commercial uptake uncertainty"
    ]
  },
  "catalysts": {
    "near_term": [
      "Updated commercial sales numbers",
      "Manufacturing scale updates",
      "New clinical data readouts"
    ],
    "long_term": [
      "Earlier-line trials",
      "European approval",
      "Pipeline TIL expansions"
    ]
  },
  "red_flags": [
    "High probability of dilution",
    "Class-action lawsuit",
    "High variance in analyst estimates"
  ],
  "analyst_summary": {
    "analyst_target_avg": 8.25,
    "analyst_target_range_low": 1.5,
    "analyst_target_range_high": 17,
    "sentiment": "mixed"
  },
  "metadata": {
    "last_updated": "2025-12-05T00:00:00Z",
    "model_version": "1.0.0"
  }
}